Stockscreener 앱 받기
1.35
2.88%
-0.04
시간 외 거래:
1.36
0.01
+0.74%
전일 마감가:
$1.39
열려 있는:
$1.36
하루 거래량:
1.01M
Relative Volume:
1.17
시가총액:
$81.91M
수익:
-
순이익/손실:
$-22.40M
주가수익비율:
-1.9236
EPS:
-0.7018
순현금흐름:
$-18.84M
1주 성능:
+3.85%
1개월 성능:
+4.65%
6개월 성능:
+22.73%
1년 성능:
-34.47%
1일 변동 폭
$1.34
$1.446
1주일 범위
$1.29
$1.446
52주 변동 폭
$0.87
$3.19
MAIA Biotechnology Inc Stock (MAIA) Company Profile
명칭
MAIA Biotechnology Inc
전화
312 416 8592
주소
444 West Lake Street, Suite 1700, Chicago
Compare MAIA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.35 | 84.33M | 0 | -22.40M | -18.84M | -0.7018 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
MAIA Biotechnology Inc 주식(MAIA)의 최신 뉴스
Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Rises By 23.0% - MarketBeat
MAIA Biotechnology (MAIA) Projected to Post Quarterly Earnings on Friday - MarketBeat
MAIA Biotechnology (MAIA) price target increased by 18.16% to 12.38 - MSN
BREAKING: TRUMP JUST BOUGHT THIS STOCK! (01ajqP9sss) - fathomjournal.org
MAIA Biotechnology (MAIA) posts narrower Q4 2025 loss than analyst estimates, lifting shares 4.44 percent today.Joint Venture - Newser
MAIA Biotechnology | 8-K: Current report - Moomoo
MAIA Biotechnology opens first U.S. site for lung cancer trial By Investing.com - Investing.com Australia
MAIA Should I Buy - Intellectia AI
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Update - MarketBeat
MAIA Biotechnology opens first U.S. site for lung cancer trial - Investing.com
MAIA Expands THIO-101 Lung Cancer Trial in U.S. - TipRanks
MAIA Biotechnology activates first U.S. site for THIO-101 Phase 2 expansion, NIH funds $2.3M - TradingView
MAIA Biotechnology Activates First U.S. Site for THIO-101 Phase 2 Trial, Reporting Promising Efficacy in Advanced NSCLC Treatment - Quiver Quantitative
Form 8-KCurrent report - ADVFN
MAIA Biotechnology Activates First U.S. Site for Ongoing - GlobeNewswire
MAIA Biotechnology (MAIA) CEO awarded 800,000 stock options at $1.28 - Stock Titan
[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity - Stock Titan
MAIA Biotechnology (MAIA) grants 30,000 stock options to finance head - Stock Titan
EPS Watch: How do insiders feel about MAIA Biotechnology IncMarket Movement Recap & Safe Capital Growth Plans - baoquankhu1.vn
Aug Drivers: How does MAIA Biotechnology Inc compare to its peersMarket Risk Summary & Real-Time Sentiment Analysis - baoquankhu1.vn
Value Recap: Is MAIA Biotechnology Inc trading at a discountLayoff News & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Short Covering: Is MAIA Biotechnology Inc stock forming a cup and handle2026 Sector Review & Free Reliable Trade Execution Plans - baoquankhu1.vn
Earnings Report: Is MAIA Biotechnology Inc stock forming a cup and handle - baoquankhu1.vn
Is MAIA Biotechnology (MAIA) Stock Slowing Down | Price at $1.25, Up 4.58%Profit Surge - Newser
Day Trade: What are the future prospects of MAIA Biotechnology IncBond Market & AI Optimized Trade Strategies - baoquankhu1.vn
MAIA Biotechnology Raises $33M to Fully Fund Pivotal Phase 3 Trial of Ateganosine for Advanced NSCLC Treatment - Minichart
Earnings Recap: Is MAIA Biotechnology Inc in a long term uptrend2026 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
MAIA Fully Funds Pivotal Phase 3 THIO-104 NSCLC Trial - TipRanks
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy - The Manila Times
MAIA Biotechnology says $33M raise should fully fund pivotal Phase 3 trial of ateganosine - TradingView
MAIA (NYSE: MAIA) uses $33M raise to fund Phase 3 lung cancer study - Stock Titan
MAIA Biotechnology Expects Recent $33 Million Capital Raise - GlobeNewswire
MAIA Biotechnology (NYSE American: MAIA) plans 2026 virtual shareholder meeting, pay vote - Stock Titan
MAIA Biotechnology | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Is MAIA Biotechnology (MAIA) Stock Good for Long Term | Price at $1.29, Down 3.01%Sector Leader - Newser
MAIA Biotechnology Awards Executive Bonuses After Successful Financing - TipRanks
MAIA Biotechnology (NASDAQ: MAIA) director receives 27,258 stock options at $1.40 - Stock Titan
MAIA Biotechnology (MAIA) awards director 27,907 options at $1.40 - Stock Titan
MAIA (MAIA) director receives grant of 27,258 stock options - Stock Titan
MAIA Biotechnology (MAIA) director granted 33,748 stock options - Stock Titan
MAIA (MAIA) director receives 28,556 stock options at $1.40 strike - Stock Titan
MAIA Biotechnology (MAIA) awards cash bonuses after recent capital raise - Stock Titan
Noble Financial Maintains MAIA Biotechnology(MAIA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Bond Watch: How does MAIA Biotechnology Inc compare to its peersEarnings Recap Report & Growth-Oriented Investment Plans - baoquankhu1.vn
MAIA Highlights Promising Phase 2 NSCLC Survival Outcomes - TipRanks
Treasury Yields: Is now the right time to enter MAIA Biotechnology Inc2026 Price Momentum & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
MAIA Biotechnology reports >2-year overall survival for 8 NSCLC patients in Phase 2 THIO-101 - TradingView — Track All Markets
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer - The Manila Times
Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer - TradingView
Eight MAIA (NYSE: MAIA) NSCLC patients top two-year survival on Phase 2 regimen - Stock Titan
After prior treatment failed, 8 lung cancer patients lived past 2 years - Stock Titan
MAIA Biotechnology Inc (MAIA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):